Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.71 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.71 |
| ▸ | CLK2 | P49760 | 2/20 | 0.71 |
| ▸ | GSK3B | P49841 | 2/20 | 0.71 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.71 |
| ▸ | MELK | Q14680 | 2/20 | 0.71 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.71 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.71 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | NQO2 | P16083 | 1/20 | 0.71 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.71 |
| ▸ | FECH | P22830 | 1/20 | 0.71 |
| ▸ | JAK1 | P23458 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532858 | 0.89 | MAPK8 (0.71) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL7107914 | 0.87 | MAPK8 (0.67) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL5372290 | 0.86 | MAPK8 (0.67) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL5374929 | 0.85 | MAPK8 (0.66) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL5373334 | 0.84 | CLK2 (0.98) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL5380287 | 0.83 | MAPK8 (0.71) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| Cc-401 SCHEMBL4604749 | 0.83 | CLK2 (1.00) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| SCHEMBL8253744 | 0.83 | CLK2 (1.00) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| Cc-401 SCHEMBL30290855 | 0.83 | CLK2 (1.00) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 | |
| Cc-401 SCHEMBL23924447 | 0.82 | CLK2 (0.98) | MAPK8DYRK3PRKD3MAP4K4CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAPK8 26/4885DYRK3 1308/4885PRKD3 135/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPK8 25/4885DYRK3 805/4885PRKD3 70/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPK8 26/4885DYRK3 681/4885PRKD3 79/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPK8 25/4885DYRK3 805/4885PRKD3 70/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAPK8 91/4885DYRK3 373/4885PRKD3 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.